Nuclear Factor-KappaB Modulation As a Therapeutic Approach in Hematologic Malignancies

Cancer

Volumn 100, Issue 8, 2004, Pages 1578-1589

  Panwalkar, Amit ^a   Verstovsek, Srdan ^a   Giles, Francis ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bcl 3; Bortezomib; Hodgkin disease; Leukemia; Nuclear factor kappaB; Nuclear factor kappaB inhibitor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; BMS 34551; BORTEZOMIB; CELL ADHESION MOLECULE; CYTOKINE; ENZYME INHIBITOR; GROWTH FACTOR; I KAPPA B; I KAPPA B KINASE; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGENIC AGENT; PROTEIN P50; SC 514; SPC 839; TEMSIROLIMUS; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANGIOGENESIS; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE REPRESSION; GENETIC TRANSCRIPTION; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; LEUKEMIA; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; STRESS; TRANSCRIPTION INITIATION;

CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; HEMATOLOGIC NEOPLASMS; HUMANS; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 1842425016     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20182     Document Type: Review

References (146)

1. Sun SC, Xiao G. Deregulation of NF-kappaB and its upstream kinases in cancer. Cancer Metastasis Rev. 2003;22: 405-422.
2. Ruland J, Mak TW. Transducing signals from antigen receptors to nuclear factor kappaB. Immunol Rev. 2003;193:93-100.
3. Horie R, Higashihara M, Watanabe T. Hodgkin's lymphoma and CD30 signal transduction. Int J Hematol. 2003;77:37-47.
4. Schatmer EJ. CD40 ligand in CLL pathogenesis and therapy. Leuk Lymphoma. 2000;37:461-472.
5. Amit S, Ben-Neriah Y. NF-kappaB activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach. Semin Cancer Biol. 2003;13:15-28.
6. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 1994;12:141-179.
7. Bours V, Bentires-Alj M, Hellin AC, et al. Nuclear factor-kappa B, cancer, and apoptosis. Biochem Pharmacol. 2000; 60:1085-1089.
8. Haefner B. NF-kappa B: arresting a major culprit in cancer. Drug Discov Today. 2002;7:653-663.
9. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell. 1986;46:705-716.
10. Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA. Phylogenetic perspectives in innate immunity. Science. 1999; 284:1313-1318.
11. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621-663.
12. Lee C, Schwartz MP, Prakash S, Iwakura M, Matouschek A. ATP-dependent proteases degrade their substrates by processively unraveling them from the degradation signal. Mol Cell. 2001;7:627-637.
13. Lin L, Ghosh S. A glycine-rich region in NF-kappaB p105 functions as a processing signal for the generation of the p50 subunit. Mol Cell Biol. 1996;16:2248-2254.
14. Orian A, Schwartz AL, Israel A, Whiteside S, Kahana C, Ciechanover A. Structural motifs involved in ubiquitin-mediated processing of the NF-kappaB precursor p105: roles of the glycine-rich region and a downstream ubiquitination domain. Mol Cell Biol. 1999;19:3664-3673.
15. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell. 1996;87:13-20.
16. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999;18:6938-6947.
17. Brown AM, Linhoff MW, Stein B, et al. Function of NF-kappa B/Rel binding sites in the major histocompatibility complex Class II invariant chain promoter is dependent on cell-specific binding of different NF-kappa B/Rel subunits. Mol Cell Biol. 1994;14:2926-2935.
18. Hansen SK, Baeuerle PA, Blasi F. Purification, reconstitution, and I kappa B association of the c-Rel-p65 (RelA) complex, a strong activator of transcription. Mol Cell Biol. 1994;14:2593-2603.
19. Hansen SK, Guerrini L, Blasi F. Differential DNA sequence specificity and regulation of HIV-1 enhancer activity by cRel-RelA transcription factor. J Biol Chem. 1994;269:22230-22237.
20. Kang SM, Tran AC, Grilli M, Lenardo MJ. NF-kappa B subunit regulation in nontransformed CD4+ T lymphocytes. Science. 1992;256:1452-1456.
21. Plaksin D, Baeuerle PA, Eisenbach L. KBF1 (p50 NF-kappa B homodimer) acts as a repressor of H-2Kb gene expression in metastatic tumor cells. J Exp Med. 1993;177:1651-1662.
22. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225-260.
23. Santoro MG, Rossi A, Amici C. NF-kappaB and virus infection: who controls whom? EMBO J. 2003;22:2552-2560.
24. Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M. Identification and characterization of an IkappaB kinase. Cell. 1997;90:373-383.
25. Rothwarf DM, Zandi E, Natoli G, Karin M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature. 1998;395:297-300.
26. Cohen L, Henzel WJ, Baeuerle PA. IKAP is a scaffold protein of the IkappaB kinase complex. Nature. 1998;395:292-296.
27. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell. 1997;91:243-252.
28. Zandi E, Chen Y, Karin M. Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate. Science. 1998;281:1360-1363.
29. Yamaoka S, Courtois G, Bessia C, et al. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell. 1998;93:1231-1240.
30. Delhase M, Hayakawa M, Chen Y, Karin M. Positive and negative regulation of IkappaB kinase activity through IKK-beta subunit phosphorylation. Science. 1999;284:309-313.
31. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066-1071.
32. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene. 1999;18:943-953.
33. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100:2961-2969.
34. Gilmore T, Gapuzan ME, Kalaitzidis D, Starczynowski D. Rel/NF-kappa B/I kappa B signal transduction in the generation and treatment of human cancer. Cancer Lett. 2002; 181:1-9.
35. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001;107:241-246.
36. Silverman N, Maniatis T. NF-kappaB signaling pathways in mammalian and insect innate immunity. Genes Dev. 2001; 15:2321-2342.
37. Israel A. The IKK complex: an integrator of all signals that activate NF-kappaB? Trends Cell Biol. 2000;10:129-133.
38. Makris C, Roberts JL, Karin M. The carboxyl-terminal region of IkappaB kinase gamma (IKKgamma) is required for full IKK activation. Mol Cell Biol. 2002;22:6573-6581.
39. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 2001;8:739-758.
40. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol. 2000;20:2687-2695.
41. Wang CY, Guttridge DC, Mayo MW, Baldwin AS Jr. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol. 1999;19:5923-5929.
42. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281:1680-1683.
43. Kiriakidis S, Andreakos E, Monaco C, Foxwell B, Feldmann M, Paleolog E. VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2. J Cell Sci. 2003;116:665-674.
44. Zhong H, Voll RE, Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell. 1998;1:661-671.
45. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 2000;406:86-90.
46. Chen L, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science. 2001;293:1653-1657
47. Baldwin AS Jr., Azizkhan JC, Jensen DE, Beg AA, Coodly LR. Induction of NF-kappa B DNA-binding activity during the G0-to-G1 transition in mouse fibroblasts. Mol Cell Biol. 1991;11:4943-4951.
48. Perkins ND, Felzien LK, Betts JC, Leung K, Beach DH, Nabel GJ. Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science. 1997;275:523-527.
49. Bash J, Zong WX, Gelinas C. c-Rel arrests the proliferation of HeLa cells and affects critical regulators of the G1/S-phase transition. Mol Cell Biol. 1997;17:6526-6536.
50. Otsuka G, Nagaya T, Saito K, Mizuno M, Yoshida J, Seo H. Inhibition of nuclear factor-kappaB activation confers sensitivity to tumor necrosis factor-alpha by impairment of cell cycle progression in human glioma cells. Cancer Res. 1999; 59:4446-4452.
51. Kaltschmidt B, Kaltschmidt C, Hehner SP, Droge W, Schmitz ML. Repression of NF-kappaB impairs HeLa cell proliferation by functional interference with cell cycle checkpoint regulators. Oncogene. 1999;18:3213-3225.
52. Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG. NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev. 2001;12:73-90.
53. Nevins JR. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science. 1992;258:424-429.
54. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995;9:1149-1163.
55. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323-330.
56. Gilmore TD. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene. 1999; 18:6925-6937.
57. Kabrun N, Bumstead N, Hayman ML, Enrietto PJ. Characterization of a novel promoter insertion in the c-rel locus. Mol Cell Biol. 1990;10:4788-4794.
58. Abbadie C, Kabrun N, Bouali F, et al. High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro. Cell. 1993;75:899-912.
59. Hrdlickova R, Nehyba J, Humphries EH. In vivo evolution of c-rel oncogenic potential. J Virol. 1994;68:2371-2382.
60. Kralova J, Schatzle JD, Bargmann W, Bose HR Jr. Transformation of avian fibroblasts overexpressing the c-rel protooncogene and a variant of c-rel lacking 40 C-terminal amino acids. J Virol. 1994;68:2073-2083.
61. Nehyba J, Hrdlickova R, Humphries EH. Evolution of the oncogenic potential of v-rel: rel-induced expression of immunoregulatory receptors correlates with tumor development and in vitro transformation. J Virol. 1994;68:2039-2050.
62. Brownell E, Fell HP, Tucker PW, Geurts van Kessel AH, Hagemeijer A, Rice NR. Regional localization of the human c-rel locus using translocation chromosome analysis. Oncogene. 1988;2:527-529.
63. Mathew S, Murty VV, Dalla-Favera R, Chaganti RS. Chromosomal localization of genes encoding the transcription factors, c-rel, NF-kappa Bp50, NF-kappa Bp65, and lyt-10 by fluorescence in situ hybridization. Oncogene. 1993;8:191-193.
64. Barth TF, Dohner H, Werner CA, et al. Characteristic pattern of chromosomal gains and losses in primary large B-cell lymphomas of the gastrointestinal tract. Blood. 1998;91:4321-4330.
65. Houldsworth J, Mathew S, Rao PH, et al. REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood. 1996;87:25-29.
66. Rao PH, Houldsworth J, Dyomina K, et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood. 1998;92:234-240.
67. Joos S, Otano-Joos MI, Ziegler S, et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood. 1996;87:1571-1578.
68. Lu D, Thompson JD, Gorski GK, Rice NR, Mayer MG, Yunis JJ. Alterations at the rel locus in human lymphoma. Oncogene. 1991;6:1235-1241.
69. Carrasco D, Cheng J, Lewin A, et al. Multiple hemopoietic defects and lymphoid hyperplasia in mice lacking the transcriptional activation domain of the c-Rel protein. J Exp Med. 1998;187:973-984.
70. Schmitz ML, Stelzer G, Altmann H, Meisterernst M, Baeuerle PA. Interaction of the COOH-terminal transactivation domain of p65 NF-kappa B with TATA-binding protein, transcription factor IIB, and coactivators. J Biol Chem. 1995;270: 7219-7226.
71. Xu X, Prorock C, Ishikawa H, Maldonado E, Ito Y, Gelinas C. Functional interaction of the v-Rel and c-Rel oncoproteins with the TATA-binding protein and association with transcription factor IIB. Mol Cell Biol. 1993;13:6733-6741.
72. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature. 1995;376:167-170.
73. Trecca D, Guerrini L, Fracchiolla NS, et al. Identification of a tumor-associated mutant form of the NF-kappaB RelA gene with reduced DNA-binding and transactivating activities. Oncogene. 1997;14:791-799.
74. Liptay S, Schmid RM, Perkins ND, et al. Related subunits of NF-kappa B map to two distinct loci associated with translocations in leukemia, NFKB1 and NFKB2. Genomics. 1992; 13:287-292.
75. Ferrier R, Nougarede R, Doucet S, Kahn-Perles B, Imbert J, Mathieu-Mahul D. Physical interaction of the bHLH LYL1 protein and NF-kappaB1 p105. Oncogene. 1999;18:995-1005.
76. Fracchiolla NS, Lombardi L, Salina M, et al. Structural alterations of the NF-kappa B transcription factor lyt-10 in lymphoid malignancies. Oncogene. 1993;8:2839-2845.
77. Migliazza A, Lombardi L, Rocchi M, et al. Heterogeneous chromosomal aberrations generate 3' truncations of the NFKB2/lyt-10 gene in lymphoid malignancies. Blood. 1994; 84:3850-3860.
78. Neri A, Chang CC, Lombardi L, et al. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50. Cell. 1991; 67:1075-1087.
79. Thakur S, Lin HC, Tseng WT, et al. Rearrangement and altered expression of the NFKB-2 gene in human cutaneous T-lymphoma cells. Oncogene. 1994;9:2335-2344.
80. Chang CC, Zhang J, Lombardi L, Neri A, Dalla-Favera R. Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators. Mol Cell Biol. 1995;15:5180-5187.
81. Zhang J, Chang CC, Lombardi L, Dalla-Favera R. Rearranged NFKB2 gene in the HUT78 T-lymphoma cell line codes for a constitutively nuclear factor lacking transcriptional repressor functions. Oncogene. 1994;9:1931-1937.
82. Caamano JH, Rizzo CA, Durham SK, et al. Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J Exp Med. 1998;187:185-196.
83. Franzoso G, Carlson L, Poljak L, et al. Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med. 1998;187:147-159.
84. Ishikawa H, Carrasco D, Claudio E, Ryseck RP, Bravo R. Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-kappaB2. J Exp Med. 1997;186:999-1014.
85. Epinat JC, Gilmore TD. Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene. 1999;18:6896-6909.
86. Lenardo M, Siebenlist U. Bcl-3-mediated nuclear regulation of the NF-kappa B trans-activating factor. Immunol Today. 1994;15:145-147.
87. Ohno H, Takimoto G, McKeithan TW. The candidate protooncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell. 1990;60:991-997.
88. Michaux L, Mecucci C, Stul M, et al. BCL3 rearrangement and t(14;19)(q32;q13) in lymphoproliferative disorders. Genes Chromosomes Cancer. 1996;15:38-47.
89. Ohno H, Doi S, Yabumoto K, Fukuhara S, McKeithan TW. Molecular characterization of the t(14;19)(q32;q13) translocation in chronic lymphocytic leukemia. Leukemia. 1993;7: 2057-2063.
90. Franzoso G, Carlson L, Scharton-Kersten T, et al. Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture, and germinal center reactions. Immunity. 1997;6:479-490.
91. Caamano JH, Perez P, Lira SA, Bravo R. Constitutive expression of Bcl-3 in thymocytes increases the DNA binding of NF-kappaB1 (p50) homodimers in vivo. Mol Cell Biol. 1996; 16:1342-1348.
92. Ong ST, Hackbarth ML, Degenstein LC, Baunoch DA, Anastasi J, McKeithan TW. Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice. Oncogene. 1998;16:2333-2343.
93. Karin M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene. 1999;18:6867-6874.
94. Beauparlant P, Kwan I, Bitar R, et al. Disruption of I kappa B alpha regulation by antisense RNA expression leads to malignant transformation. Oncogene. 1994;9:3189-3197.
95. Beg AA, Sha WC, Bronson RT, Baltimore D. Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient mice. Genes Dev. 1995;9:2736-2746.
96. Klement JF, Rice NR, Car BD, et al. IkappaBalpha deficiency results in a sustained NF-kappaB response and severe wide-spread dermatitis in mice. Mol Cell Biol. 1996;16:2341-2349.
97. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene. 1999;18:3063-3070.
98. Wood KM, Roff M, Hay RT. Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB. Oncogene. 1998;16:2131-2139.
99. Devalaraja MN, Wang DZ, Ballard DW, Richmond A. Elevated constitutive IkappaB kinase activity and IkappaB-alpha phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-alpha transcription. Cancer Res. 1999;59:1372-1377.
100. Newton TR, Patel NM, Bhat-Nakshatri P, Stauss CR, Goulet RJ Jr., Nakshatri H. Negative regulation of transactivation function but not DNA binding of NF-kappaB and AP-1 by IkappaBbetal in breast cancer cells. J Biol Chem. 1999;274: 18827-18835.
101. Le Beau MM, Ito C, Cogswell P, Espinosa R III, Fernald AA, Baldwin AS Jr. Chromosomal localization of the genes encoding the p50/p105 subunits of NF-kappa B (NFKB2) and the I kappa B/MAD-3 (NFKB1) inhibitor of NF-kappa B to 4q24 and 14q13, respectively. Genomics. 1992;14:529-531.
102. Koduru PR, Susin M, Schulman P, et al. Phenotypic and genotypic characterization of Hodgkin's disease. Am J Hematol. 1993;44:117-124.
103. Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood. 1996;87:4340-4347.
104. Gruss HJ, Pinto A, Duyster J, Poppema S, Herrmann F. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today. 1997;18:156-163.
105. Fiumara P, Snell V, Li Y, et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood. 2001;98:2784-2790.
106. Younes A, Garg A, Aggarwal BB. Nuclear transcription factor-kappaB in Hodgkin's disease. Leuk Lymphoma. 2003;44: 929-935.
107. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia. 2000;14:399-402.
108. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev. 1998;12:968-981.
109. Sun SC, Maggirwar SB, Harhaj EW, Uhlik M. Binding of c-Rel to STAT5 target sequences in HTLV-1-transformed T cells. Oncogene. 1999;18:1401-1409.
110. Baumgartner B, Weber M, Quirling M, et al. Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts. Leukemia. 2002;16:2062-2071.
111. Mori N, Fujii M, Ikeda S, Yamada Y, Tomonaga M, Ballard DW, et al. Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood. 1999;93:2360-2368.
112. Davis IN, Kucuk O, Djuric Z, Sarkar FH. Soy isoflavone supplementation in healthy men prevents NF-kappa B activation by TNF-alpha in blood lymphocytes. Free Radic Biol Med. 2001;30:1293-1302.
113. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301-2307.
114. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schatmer EJ. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol. 2000;164: 2200-2206.
115. Knecht H, Berger C, Rothenberger S, Odermatt BF, Brousset P. The role of Epstein-Barr virus in neoplastic transformation. Oncology, 2001;60:289-302.
116. Kirchner D, Duyster J, Ottmann O, Schmid RM, Bergmann L, Munzert G. Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation. Exp Hematol. 2003;31:504-511.
117. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappaB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003;171:88-95.
118. Zaninoni A, Imperiali FG, Pasquini C, Zanella A, Barcellini W. Cytokine modulation of nuclear factor-kappaB activity in B-chronic lymphocytic leukemia. Exp Hematol. 2003;31:185-190.
119. Ohshima K, Muta H, Kawasaki C, et al. Bcl10 expression, rearrangement and mutation in MALT lymphoma: correlation with expression of nuclear factor-kappaB. Int J Oncol. 2001;19:283-289.
120. Ruland J, Duncan GS, Elia A, et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. Cell. 2001;104:33-42.
121. Yoneda T, Imaizumi K, Maeda M, et al. Regulatory mechanisms of TRAF2-mediated signal transduction by Bcl10, a MALT lymphoma-associated protein. J Biol Chem. 2000;275: 11114-11120.
122. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998;396:77-80.
123. Pan MH, Lin-Shiau SY, Lin JK. Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages. Biochem Pharmacol. 2000;60:1665-1676.
124. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood. 2003;101: 1053-1062.
125. Gautam SC, Xu YX, Pindolia KR, Janakiraman N, Chapman RA. Nonselective inhibition of proliferation of transformed and nontransformed cells by the anticancer agent curcumin (diferuloylmethane). Biochem Pharmacol. 1998;55:1333-1337.
126. Lyss G, Schmidt TJ, Merfort I, Pahl HL. Helenalin, an anti-inflammatory sesquiterpene lactone from Arnica, selectively inhibits transcription factor NF-kappaB. Biol Chem. 1997; 378:951-961.
127. Dirsch VM, Stuppner H, Vollmar AM. Cytotoxic sesquiterpene lactones mediate their death-inducing effect in leukemia T cells by triggering apoptosis. Planta Med. 2001;67: 557-559.
128. Dirsch VM, Stuppner H, Vollmar AM. Helenalin triggers a CD95 death receptor-independent apoptosis that is not affected by overexpression of Bcl-x(L) or Bcl-2. Cancer Res. 2001;61:5817-5823.
129. Munzert G, Kirchner D, Stobbe H, et al. Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis. Blood. 2002;100:3749-3756.
130. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000;119:1209-1218.
131. Liu P, Han ZC. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies. Int J Hematol. 2003;78: 32-39.
132. Mathas S, Lietz A, Janz M, et al. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood. 2003;102:1028-1034.
133. Pan Q, Bao LW, Merajver SD. Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. Mol Cancer Res. 2003;1:701-706.
134. Berenson JR, Ma HM, Vescio R. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin Oncol. 2001;28:626-633.
135. Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood. 2003;101:3126-3135.
136. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood. 2003; 102:3765-3774.
137. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res. 2003; 9:6316-6325.
138. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappaB system: a treasure trove for drug development. Nat Rev Drug Discov. 2004;3:17-26.
139. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood. 2004;103:20-32.
140. Palanki MS, Gayo-Fung LM, Shevlin GI, et al. Structure-activity relationship studies of ethyl 2-[(3-methyl-2,5-dioxo(3-pyrrolinyl)) amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate: an inhibitor of AP-1 and NF-kappaB mediated gene expression. Bioorg Med Chem Lett. 2002;12:2573-2577.
141. Castro AC, Dang LC, Soucy F, et al. Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett. 2003;13:2419-2422.
142. Burke JR, Pattoli MA, Gregor KR, et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem. 2003;278:1450-1456.
143. Kishore N, Sommers C, Mathialagan S, et al. A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts. J Biol Chem. 2003;278:32861-32871.
144. Jana NR, Dikshit P, Goswami A, Nukina N. Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem. 2003. Dec 30 [Epub ahead of print].
145. Ravandi F, Talpaz M, Estrov Z. Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies. Clin Cancer Res. 2003;9:535-550.
146. Giles FJ. The emerging role of angiogenesis inhibitors in hematologic malignancies. Oncology (Huntingt). 2002;16:23-29.